Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy (MIST-A)
Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Fang Yang, Ph.D
- Phone Number: 86-029-84771319
- Email: fyangx@fmmu.edu.cn
Study Contact Backup
- Name: Wen Jiang, Ph.D
- Phone Number: 86-029-84771319
- Email: jiangwen@fmmu.edu.cn
Study Locations
-
-
-
Xi'an, China
- Xijing Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion;
- Age 18-85 years old;
- The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging;
- The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6;
- Preoperative NIHSS score ranges from 6 to 30 points;
- Sign the informed consent form;
Exclusion Criteria:
- There are contraindications for mechanical thrombectomy;
- No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b;
- There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc;
- There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction;
- Renal insufficiency or hepatic insufficiency (serum creatinine >2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value);
- Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months;
- There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results;
- Pre-existing neurological deficits or history of dementia;
- There are infectious diseases that require antibiotic treatment before the disease;
- Allergic to tetracyclines or unable to take minocycline for other reasons;
- Minocycline could not be given within 1 hour after recanalization;
- Pregnant patients;
- Participated in another clinical trial within 30 days before inclusion in the study.
- Refuse to sign the informed consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Minocycline treatment group
Patients were given minocycline 200mg/d orally from the day of admission for 5 days.
At the same time, the patient received mechanical thrombectomy and other standard treatments for acute ischemic stroke.
|
Minocycline is a tetracycline antibiotic.
Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.
|
|
No Intervention: Routine treatment group
Patients were given mechanical thrombectomy and other standard treatment for acute ischemic stroke, without minocycline treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in infarct volume from baseline to day 5
Time Frame: Day 5 after onset
|
Baseline infarct volume is measured by diffusion-weighted imaging (DWI), day 5 infarct volume is measured by fluid attenuated inversion recovery (FLAIR), Images are processed by imSTROKE software.
|
Day 5 after onset
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional outcome at 3 months after onset
Time Frame: 3 months after onset
|
Defined by the modified Rankin Scale (mRS), which ranges from 0 (no symptoms) to 6 (death), analyzed for superiority and then for noninferiority.
|
3 months after onset
|
|
Favourable outcome at 3 months after onset
Time Frame: 3 months after onset
|
Defined as proportion of patients with modified Rankin Scale (mRS) 0-2, which ranges from 0 (no symptoms) to 6 (death), An mRS score of <3 indicated a favourable outcome, whereas a score of ≥3 indicated a poor outcome.
|
3 months after onset
|
|
Excellent outcome at 3 months after onset
Time Frame: 3 months after onset
|
Defined as proportion of patients with modified Rankin Scale (mRS) 0-1, which ranges from 0 (no symptoms) to 6 (death), An mRS score of <2 indicated a excellent outcome, whereas a score of ≥2 indicated a poor outcome.
|
3 months after onset
|
|
Improvement of neurological function compared with baseline
Time Frame: day 1, day 3, day 5, day 7, and 3 months after onset
|
Defined by the National Institute of Health Stroke Scale (NIHSS), which ranges from 0 (no neurological injury) to 42 (severe neurological injury).
The assessment time points were baseline, day 1, day 3, day 5, day 7, and 3 months after onset.
|
day 1, day 3, day 5, day 7, and 3 months after onset
|
|
Improvement of activity of daily living at 3 months after onset
Time Frame: 3 months after onset
|
Defined by Barthel index (BI), which ranges from 0 (completely lose the ability to live independently) to 100 (complete ability to live independently).
The assessment time points were 3 months after onset
|
3 months after onset
|
|
Incidence of intracranial hemorrhage at day 1 after onset
Time Frame: Day 1 after onset
|
Intracranial hemorrhage is measured by CT scan.
Images are processed by RAPID ICH software.
|
Day 1 after onset
|
|
Mortality at 3 months after onset
Time Frame: 3 months after onset
|
The investigators record all-cause mortality
|
3 months after onset
|
|
Length of hospital stay and length of Intensive Care Unit (ICU) stay
Time Frame: 3 months after onset
|
How long the patients stay in hospital, and how long the patients stay in ICU
|
3 months after onset
|
|
Infarct volume at day 5 after onset
Time Frame: Day 5 after onset
|
Day 5 infarct volume is measured by fluid attenuated inversion recovery (FLAIR).
Images are processed by imSTROKE software.
|
Day 5 after onset
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety outcomes: adverse events and serious adverse events
Time Frame: 3 months after onset
|
Safety outcomes were incidences of adverse events and serious adverse events that were related or not related to the study treatment.
|
3 months after onset
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
- Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006 Apr;37(4):1087-93. doi: 10.1161/01.STR.0000206281.77178.ac. Epub 2006 Feb 23.
- Matsukawa N, Yasuhara T, Hara K, Xu L, Maki M, Yu G, Kaneko Y, Ojika K, Hess DC, Borlongan CV. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci. 2009 Oct 6;10:126. doi: 10.1186/1471-2202-10-126.
- Liao TV, Forehand CC, Hess DC, Fagan SC. Minocycline repurposing in critical illness: focus on stroke. Curr Top Med Chem. 2013;13(18):2283-90. doi: 10.2174/15680266113136660160.
- Yang Y, Salayandia VM, Thompson JF, Yang LY, Estrada EY, Yang Y. Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery. J Neuroinflammation. 2015 Feb 10;12:26. doi: 10.1186/s12974-015-0245-4.
- Muhammad S, Planz O, Schwaninger M. Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection. Cerebrovasc Dis Extra. 2016;6(2):50-9. doi: 10.1159/000447750. Epub 2016 Aug 25.
- Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC. Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study. Stroke. 2010 Oct;41(10):2283-7. doi: 10.1161/STROKEAHA.110.582601. Epub 2010 Aug 12.
- Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007 Oct 2;69(14):1404-10. doi: 10.1212/01.wnl.0000277487.04281.db.
- Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Chang I, Muralidharan K, Gheuens S, Mehta L, Elkind MSV. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15.
- Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11.
- Zhang X, Wei D, Li Y, Zhang H, Yao L, Yuan X, Liu W, Ma X, Wang B, Qin N, Li D, Shi R, Fan Z, Wang X, Wang L, Liu Z, Wang L, Wang D, Zhao J, Jiang W; MIST-A Study Group. Efficacy and safety of minocycline on patients with acute anterior circulation ischaemic stroke undergoing mechanical thrombectomy (MIST-A): a multicentre, prospective, randomised, open-label, blinded-endpoint, phase 2 trial. Lancet Reg Health West Pac. 2026 Jun 5;71:101898. doi: 10.1016/j.lanwpc.2026.101898. eCollection 2026 Jun.
- Zhang X, Zhao J, Sun Z, Wei D, Yao L, Li W, Zhu H, Liu W, Zhang H, Yuan X, Ma X, Meng J, Wang B, Jia Y, Qin N, Jiang W; MIST-A Study Group. Effects of minocycline on patients with acute anterior circulation ischaemic stroke undergoing intravenous thrombectomy (MIST-A): the study protocol for a multicentre, prospective, randomised, open-label, blinded-endpoint trial. BMJ Open. 2024 Dec 20;14(12):e093443. doi: 10.1136/bmjopen-2024-093443.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Stroke
- Ischemic Stroke
- cyclopia sequence
- Organic Chemicals
- Hydrocarbons
- Hydrocarbons, Cyclic
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Naphthacenes
- Tetracyclines
- Minocycline
Other Study ID Numbers
Other Study ID Numbers
- XJLL-KY20222186
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.